US painkiller restriction linked to 'significant' increase in illicit online drug trading

June 13, 2018, British Medical Journal
Credit: CC0 Public Domain

The US Drug Enforcement Administration's decision to restrict prescription drugs containing hydrocodone (a popular opioid painkiller) was associated with a 'significant' increase in illicit trading of opioids through online markets, finds a study published by The BMJ today.

In this study, the term opioids refers to drugs that are usually available by prescription but here are sourced illegally through the dark net and are not prescribed by anyone.

The findings show that the proportion of sales of opioids through illicit markets doubled over the study period and sales of more potent opioids also increased.

Overdose death rates have quadrupled in the US since 1999, and 40% of all deaths involve prescription opioids, which are primarily used for pain relief.

In October 2014, the US Drug Enforcement Administration decided to move hydrocodone opioids from schedule III to schedule II (a more restrictive category), making it more difficult for patients to access these drugs on prescription and stopping automatic repeat .

There is concern that users will source drugs from illegal online markets called 'cryptomarkets' rather than from pharmacies. Users only access these cryptomarkets via the 'darknet', where people can sell and buy drugs anonymously.

Although the legitimate supply of opioids may have decreased, overall consumption will remain unchanged if users decide to source them from illicit markets.

So an international research team set out to investigate whether there was a link between the 2014 reclassification of hydrocodone opioids and an increase in trading of illicit prescription drugs on cryptomarkets.

Using web crawler software, they compared sales for prescription drugs containing hydrocodone with other and illicit opioids from 31 different cryptomarkets operating from September 2013 to July 2016 (before and after reclassification).

They looked at three pieces of information from each product listing placed by a seller: the type on offer, the country from where products would be shipped, and the number of reviews the listing had received, to compare usage in relation to the 2014 reclassification.

The researchers found that the sale of opioids through US cryptomarkets increased after the 2014 reclassification, with no significant changes in sales of sedatives, steroids, stimulants, or illicit opioids.

In July 2016, sales of opioids through US cryptomarkets represented 13.7% of all drug sales compared with a modelled estimate of 6.7% of all sales (a 4% yearly increase in market share) had the new schedule not been introduced.

They also report a change in the type of drugs purchased after reclassification. Oxycodone purchases decreased, and fentanyl (a stronger and potent than hydrocodone) moved from being the least sold product to being the second most popular prescription opioid bought from cryptomarket sellers based in the USA. Fentanyl is currently the leading cause of opioid overdose in the USA.

The researchers outline some study limitations. For example, there may have been a general increase in demand that was unrelated to the 2014 restriction, and the source and destination of the drugs cannot be independently confirmed.

Nevertheless, they say their results "are consistent with the possibility that the scheduled change might have directly contributed to the changes we observed in the supply of illicit opioids."

This possibility "is reinforced by the fact that the increased availability and sales of prescription opioids on cryptomarkets in the US after the schedule change was not replicated for cryptomarkets elsewhere," they add.

By purchasing from cryptomarkets, it becomes more difficult to track individual use of , and to offer treatment and help to users, say the authors, and they suggest strategies to minimise harm, such as dealing with over-prescribing, and making more information available to users about the nature and dangers of prescription opioid use.

"These alternatives are known to have an impact on drug use and could be employed before and after schedule changes to alleviate their negative impacts" they conclude.

In a linked editorial, Scott Hadland from Boston Medical Center's Grayken Center for Addiction and Leo Beletsky from Northeastern University School of Law and Bouvé College of Health Sciences say this analysis illustrates "the predictable consequence of cutting supply without tackling demand."

They point out that the US Department of Justice recently announced it is doubling resources allocated to combatting dark web drug sales, but argue that this approach is unlikely to succeed.

They say demand for opioids in the US will decrease sustainably "only when high-quality evidence-based prevention and treatment programs are broadly implemented, robustly funded, and universally available."

And they warn that the overdose crisis "will likely worsen so long as supply-side interventions are not coupled with evidence-based measures to cut demand and reduce harm."

Explore further: FDA warns websites marketing unapproved opioids

More information: Research: Effect of restricting the legal supply of prescription opioids on buying through online illicit marketplaces: interrupted time series analysis, www.bmj.com/content/361/bmj.K2270

Editorial: Tighter prescribing regulations drive illicit opioid sales, www.bmj.com/content/361/bmj.K2480

Related Stories

FDA warns websites marketing unapproved opioids

June 11, 2018
(HealthDay)—Nine online networks, operating 53 websites, have been warned that they must stop illegally marketing potentially dangerous, unapproved, and misbranded versions of opioid medications, according to the U.S. Food ...

Nearly one in three people know someone addicted to opioids

May 8, 2018
The opioid crisis continues to weigh heavily on the minds of Americans, according to a new national poll released today by the American Psychiatric Association, (APA). Nearly a third of Americans say they know someone who ...

White House launches anti-opioid ad campaign aimed at youth

June 7, 2018
The White House launched a series of new advertisements Thursday aimed at warning young people about the dangers of opioids, taking another step in the effort to turn the tide against the deadly epidemic.

Opioid overdoses in ERs up 30 percent as crisis worsens

March 6, 2018
Emergency rooms saw a big jump in overdoses from opioids last year—the latest evidence the nation's drug crisis is getting worse.

Fentanyl now drives drug overdose deaths in U.S.

May 1, 2018
(HealthDay)—Overdose deaths involving dangerous synthetic opioids like fentanyl have skyrocketed in recent years, surpassing deaths from prescription painkillers, a new U.S. study reveals.

Let's talk about Rx use—recognizing and reversing an overdose

March 23, 2018
According to the National Institute on Drug Abuse, the misuse of and addiction to opioids is a serious national crisis, with more than 115 Americans dying from opioid overdose every day. Knowing how to prevent and recognize ...

Recommended for you

Discovery opens door for synthetic opioids with less addictive qualities

June 1, 2018
Making opioids from sugar instead of from field grown opium poppies has the potential to solve many of the problems associated with manufacturing strong pain killers.

US doctors prescribing fewer opioid painkillers: report

May 31, 2018
US doctors reduced the number of prescriptions for opioid painkillers last year, continuing a five-year trend, in an effort to reverse a deadly drug abuse epidemic, a report released Thursday said.

Researchers publish study on new therapy to treat opioid use disorder

May 22, 2018
Better delivery of medications to treat opioid use disorder (OUD) is key to addressing the opioid crisis and helping the 2.6 million Americans affected by the disease.

Could nonprofit drug companies cut sky-high prices?

May 17, 2018
(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

Fewer antibiotics for kids, but more ADHD drugs

May 15, 2018
(HealthDay)—American kids are taking fewer prescription medications these days—but certain drugs are being prescribed more than ever, a new government study finds.

Opioid makers' perks to docs tied to more prescriptions

May 14, 2018
Doctors who accept perks from companies that make opioid painkillers are more likely to prescribe the drugs for their patients, new research suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.